Lakefront Biotherapeutics | GLPG - Gross Profit On Sales


Lakefront Biotherapeutics reported EUR1.68M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Biogen USD 2.12B 307M Jun/2026
Genmab DKK 1.07B 240M Jun/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
GRIFOLS EUR 704M 84M Jun/2026
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Incyte USD 1.57B 400.89M Jun/2026
Merck EUR 3.07B 104M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
UCB EUR 3.19B 621M Dec/2025
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026